Compare TFSL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFSL | ERAS |
|---|---|---|
| Founded | 1938 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | 2006 | 2021 |
| Metric | TFSL | ERAS |
|---|---|---|
| Price | $18.21 | $17.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 717.6K | ★ 4.7M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | 14.29 | ★ 36.23 |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $115.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.54 | $1.33 |
| 52 Week High | $18.53 | $24.28 |
| Indicator | TFSL | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 48.36 |
| Support Level | $13.21 | $12.36 |
| Resistance Level | $18.53 | $18.20 |
| Average True Range (ATR) | 0.28 | 1.24 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 86.96 | 7.23 |
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.